KP Tissue, Inc.

As of June 30, 2026, KP Tissue, Inc. carries a market capitalization of 83.23M, placing it among publicly traded companies globally. Its enterprise value stands at 83.23M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

KP Tissue, Inc.'s next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, KP Tissue, Inc. has 10.03M shares outstanding.

As of June 30, 2026, KP Tissue, Inc. trades at a trailing price-to-earnings ratio of 15.31.

As of June 30, 2026, KP Tissue, Inc. trades at an EV/EBITDA multiple of 401.63 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. Its EV/EBIT multiple of 401.63 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 83.23M versus a market cap of 83.23M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, KP Tissue, Inc. maintains a current ratio of 1.00, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, KP Tissue, Inc. posted a return on equity (ROE) of 12.46, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 0.48 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 12.12, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 12.46, useful for judging operating efficiency across full business cycles. The company generates approximately - - in revenue per employee across its workforce of 3,000.00, a quick read on workforce productivity versus industry peers.

As of the close on September 28, 2026, KP Tissue, Inc.'s stock has gained approximately 15.33% over the past 52 weeks. The 50-day moving average sits at 7.88, while the 200-day moving average is 7.20.

Over the twelve months ended June 30, 2026, KP Tissue, Inc. generated - - in revenue and converted that into 5.43M in net income, yielding earnings per share of 0.54. EBITDA reached 207,228.53, while operating income came in at - -.

These figures are as of June 30, 2026. Total book value stands at 44.85M, with working capital of - - providing operational flexibility.

Over the twelve months ended June 30, 2026, KP Tissue, Inc. paid dividends of 0.43 per share. The dividend payout ratio of 78.89 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at - -, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 5.15, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to KP Tissue, Inc. shareholders.

As of June 30, 2026, KP Tissue, Inc. has an Altman Z-Score of 36.33, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.